Servier announced that sales of Effient®, its innovative last-generation antiplatelet agent, began in Russia in March 2018.
The license agreement covering the territory of Russia was signed with Daiichi Sankyo in July 2016. In this case, Servier is the registration certificate holder.
Effient® is registered in more than 65 countries, including the UK, France, Germany, Italy, Spain, Ireland, and the USA.
In Russia, “Effient®” is a prescription drug intended for prevention of thrombotic complications (myocardial infarction (MI), stroke, cardiovascular death) in patients with acute coronary syndrome (ACS), undergoing percutaneous coronary intervention (PCI), as well as for prevention of stent thrombosis in patients with ACS.
For Servier, this partnership will be a good opportunity to replenish its portfolio of original drugs for the treatment of cardiovascular diseases and provide patients in Russia and other EAEU member states with access to the latest treatment options.